Note 3: Restructuring and Impairment Expenses continued Ferinject The Group recognised an impairment of Ferinject IP following a deterioration in forecast cash flows and the commercial outlook across key markets, including Europe and the U.S. Impairment indicators identified during the year ended 30 June 2026 included increased actual and earlier-than-expected generic competition, resulting in price and share erosion post loss-ofexclusivity, and in lower long-term revenue expectations. The Group recognised a partial impairment charge of $1,548m. The recoverable amount is most sensitive to assumptions regarding the timing and extent of generic competition and impact from emerging regulatory changes, which directly influences future revenue, along with the discount rate as outlined in the table below. Ferinject IP (Iron) Post-tax discount rate Revenue US$m - 1% / + 1 % - 10% / + 10% Change in recoverable amount 52 / (48) (174) / 173 Impairment (reversal)/charge (52) / 48 174 / (173) Venofer The Group identified impairment indicators for Venofer IP during the year ended 30 June 2026, with earlier-than-expected and increased generic competition resulting in revised assumptions in selling price and market share erosion post loss-of-exclusivity, resulting in lower long-term revenue expectations. These developments accelerated forecast revenue erosion and reduced expected future cash flows over the remaining economic life of the asset. Accordingly, the Group recognised a partial impairment charge of $738m. The recoverable amount is most sensitive to assumptions regarding the timing of the impact of generic competition and its impact on future sales volumes and product pricing as outlined in the table below. Venofer IP (Iron) Revenue US$m - 10% / + 10% Change in recoverable amount (47) / 47 Impairment (reversal)/charge 47 / (47) Mircera The Group recognised an impairment of $301m in relation to Mircera IP following a reduction in recoverable amount driven by updated commercial assumptions and developments in the U.S reimbursement and market access environment. These factors resulted in lower forecast cash flows primarily through reduced revenue expectations. The recoverable amount remains most sensitive to assumptions regarding future revenue through changes in sales volumes and product pricing along with payer mix (representing the proportion of sales reimbursed through U.S government healthcare programs) as outlined in the table below. Mircera IP (Nephrology - Dialysis) Revenue Payer mix US$m - 10% / + 10% - 1% / + 1% Change in recoverable amount (169) / 174 33 / (33) Impairment (reversal)/charge 169 / (174) (33) / 33 101 Notes to the Financial Statements 101 CSL Limited Annual Report 2025/26
RkJQdWJsaXNoZXIy MjE2NDg3